Jaw Osteonecrosis in Patients Treated with Bisphosphonates: An Ultrastructural Study

References

• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1118.
   PubMed Web of Science ®Google Scholar
• Reid IR. Osteonecrosis of the jaw—who gets it, and why? Bone. 2009;44:4–10
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80–100.
   PubMed Web of Science ®Google Scholar
• Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999;9:S66–S80.
   PubMed Web of Science ®Google Scholar
• Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesisis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538–6544.
   PubMed Web of Science ®Google Scholar
• Reid IR, Bolland MJ, Grej AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007;41:318–320.
   PubMed Web of Science ®Google Scholar
• Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of biphosphonate by osteoclasto and non-resorbing cells. Bone. 2008;42:848–860.
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates: the experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20:137–145.
   PubMed Web of Science ®Google Scholar
• Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol. 2009;20:600–601.
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82:1459–1468.
   PubMed Web of Science ®Google Scholar
• Suria S, Mönkkönenb J, Taskinenb M, et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001;29:336–343.
   PubMed Web of Science ®Google Scholar
• Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int. 2004;75:71–77.
   PubMed Web of Science ®Google Scholar
• Nastro E, Musolino C, Allegra A, et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol. 2007;117:181–187.
   PubMed Web of Science ®Google Scholar
• Ibrahim T, Barbanti F, Marrano GG, et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist. 2008;13:330–336.
   PubMed Web of Science ®Google Scholar
• Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2008;122:S33–S45.
   Web of Science ®Google Scholar
• Baldi D, Izzotti A, Bonica P, Pera P, Pulliero A. Degenerative periodontal-diseases and oral osteonecrosis: the role of gene-environment interactions. Mutat Res Fundam Mol Mech Mugag. 2009;667:118–131.
   PubMed Web of Science ®Google Scholar
• Yamada J, Tsuno N, Kitayama J, et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res. 2009;151:115–120.
   PubMed Web of Science ®Google Scholar
• Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2009;302:1055–1061.
   Google Scholar
• Iizuka T, Matsukawa M. Potential excessive suppression of bone turnover with long-term oral bisphosphonates therapy in postmenopausal osteoporotic patients (prospective study monitored with biochemical marker of bone turnover). Bone. 2008;42:S54–S55.
   Web of Science ®Google Scholar
• Hansen T, Kunkel M, Weber A, Kirkpatrick CJ. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155–160.
   PubMed Web of Science ®Google Scholar
• Favus MJ. Diabetes and the risk of osteonecrosis of the jaw. J Clin Endocrinol Metab. 2007;92:817–818.
   PubMed Web of Science ®Google Scholar
• Lenz JH, Steiner-Krammer B, Schmidt W, Fletkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg. 2005;33:395–403.
   PubMed Web of Science ®Google Scholar
• Mehsen N, Barnetche T, Redonnet-Vernhet I, et al. Coagulopathies frequency in aseptic osteonecrosis patients. Joint Bone Spine. 2009;76:166–169.
   PubMed Web of Science ®Google Scholar
• Gebara SN, Moubayed H. Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. Am J Health Syst Pharm. 2009;66:1541–1547.
   PubMed Web of Science ®Google Scholar
• Sahni M, Guenther HL, Fleisch H, Collin, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993;91:2004–2011.
   PubMed Web of Science ®Google Scholar
• Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478–1487.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg. 2006;35:588–593.
   PubMed Web of Science ®Google Scholar
• Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med Oncol. 2008;25:346–349.
   PubMed Web of Science ®Google Scholar
• Wood J, Bonjean K, Ruetz S, et al. Novel Antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055–1061.
   PubMed Web of Science ®Google Scholar
• Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells : a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009;144:667–676.
   PubMed Web of Science ®Google Scholar
• Igarashi K, Adachi H, Mitani H, Shinoda H. Inhibitory effect of the topical administration of a bisphosphonate (risedronate) on root resorption incident to orthodontic tooth movement in rats. J Dent Res. 1996;75:1644–1649.
   PubMed Web of Science ®Google Scholar
• Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology. 2000;141:4793–4796.
   PubMed Web of Science ®Google Scholar
• Fromigue O, Kheddoumi N, Body JJ. Bisphosphonates antagonise bone growth factors effects on human breast cancer cells servival. Br J Cancer. 2003;89:178–184.
   PubMed Web of Science ®Google Scholar
• Benford HL, McGowan NWA, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001;28:465–473.
   PubMed Web of Science ®Google Scholar